Gastrohepatic Disorders

Is Doxylamine-Pyridoxine Effective for Pregnancy-Related Nausea and Vomiting?

January 18, 2018

The researchers found that the improvement in symptom scores was greater with doxylamine-pyridoxine versus placebo (0.73 points; 95% confidence interval, 0.21 to 1.25) when the last observation carried forward imputation was used for missing data.

Varubi Labeling Updated to Warn of Serious Hypersensitivity Reactions

By January 16, 2018

Anaphylaxis, anaphylactic shock and other serious hypersensitivity reactions have been reported.

Reduced Stoma-Related Care Costs With Ceramide-Infused Ostomy Skin Barrier

January 16, 2018

The researchers found that over a 12-week period there was a significant reduction in stoma-related cost of care with use of the ceramide-infused barrier, resulting in a 14% relative decrease in cost.

Treating a Common Extraintestinal Manifestation of Inflammatory Bowel Disease

January 05, 2018

Mr. C, a 30-year-old male with Crohn's disease, presented to his clinician with symptoms of fatigue, lethargy, headaches, pallor, hair loss, irritability, and weakness.

Treatment Response Predictors ID'd for Infliximab Salvage in Severe UC

January 03, 2018

Those treated with accelerated (AI) versus standard infliximab induction strategies had a numerically higher colectomy rate; however, AI treatment was correlated with more severe biochemical disease.

Effective Treatments for Nausea, Vomiting of Pregnancy

December 28, 2017

Early treatment can prevent complications; safe, effective treatment available for more severe cases

Links Between Bacterial Infection and Gallbladder Disease Investigated

December 18, 2017

Among participants ≤45 years in the H. pylori-positive group, the prevalence of gallstones was lower than in the H. pylori-negative group (odds ratio, 0.653).

Biosimilar Ixifi Gets FDA Approval for All Remicade Indications

By December 14, 2017

Ixifi is a chimeric human-murine monoclonal antibody (mAb) against tumor necrosis factor.

Sanofi Discontinues <i>C. Difficile</i> Tx Development

By December 08, 2017

Data that has been collected from the trial so far will be analyzed and shared with the scientific community in due time.

Safety and Efficacy of Switching Infliximab to Biosimilar in IBD

By December 06, 2017

Results showed that disease activity scores before and after switching were not statistically significantly different (Crohn's disease activity index: P=.5657 and Truelove-Witts disease activity index: P=.7609).

Polyethylene Glycol vs. Pulsed Irrigation Evacuation for Colon Prep

December 06, 2017

The researchers found that PIE and sodium phosphate were superior to PEG, with both receiving a score of 4 on a 5-point scale (blind assessment), versus a 3 for PEG (P<0.01).

Triple Therapy Linked to Mortality Rate in CAD With GI Bleeding

December 06, 2017

Increased mortality at 90 days in patients with lower gastrointestinal bleeding, coronary artery disease

Pediatric Ulcerative Colitis Tx Granted Orphan Drug Status

By December 04, 2017

The designation is based on a review of Phase 1b clinical data which showed potential for SER-287 as a novel treatment modality for patients with UC

IV Iron Sucrose Evaluated for Iron Deficiency Anemia in Pediatric IBD

By December 01, 2017

Results of the review also found that 18 adverse events occurred in a total of 13 patients (18.1% of patients; 6.6% of infusions).

Frequency of Celiac Disease Testing Examined in Patients with IDA

By November 30, 2017

The subgroup that was most frequently tested was young Caucasian men, with 61% of respondents stating that they would implement serologic testing in this group.

Ready-to-Drink Colonoscopy Prep Solution Gains FDA Approval

By November 29, 2017

Clenpiq will become the only FDA-approved colonoscopy prep that is 'ready-to-drink'. The solution is cranberry-flavored and the Company says it is expected to be available in Q1 of 2018.

Fecal Microbial Transplant via Oral Capsule Versus Colonoscopy

November 29, 2017

The researchers found that prevention of recurrent CDI after a single treatment was achieved by 96.2% of participants in the capsule and colonoscopy groups in the per-protocol analysis (difference, 0%), meeting the criterion for noninferiority.

New Formulation of Varubi Launched for Delayed CINV

By November 28, 2017

Varubi is a highly selective and potent antagonist of human substance P/neurokinin 1 (NK-1) receptors.

Diarrhea Med Recalled Due to Potential for Super or Sub Potent Tablets

By November 17, 2017

Diphenoxylate hydrochloride and atropine sulfate tablets are indicated as adjunctive therapy in the management of diarrhea in patients 13 years of age and older.

In ART-Treated HIV Patients With GI Discomfort, Consider EPI Assessment

By November 13, 2017

Of 100 participants, 32% had EPI (faecal elastase-1 <200 μg/g) and 20% severe EPI (faecal elastase-1 <100 μg/g).

Less Common Causes of Exocrine Pancreatic Insufficiency Explored

By November 13, 2017

Untreated celiac disease was also associated with EPI in 4% to 80% of cases but was resolved when patients adopted a gluten-free diet.

Cinvanti Approved for Chemotherapy-Induced Nausea and Vomiting

By November 10, 2017

The approval of Cinvanti was supported by Phase 2 bioequivalence data of Cinvanti and Emend IV (fosaprepitant dimeglumine; Merck), where patients treated with Cinvanti experienced fewer adverse events vs. patients treated with Emend IV, including substantially fewer infusion-site reactions.

Recall: Syringes Labeled for Sedation Med Instead Contain Antiemetic

By November 06, 2017

Dose-dependent serious cardiac arrhythmias may be observed with higher dosages of ondansetron in those patients with certain pre-existing cardiac conditions.

PPI Use May Up Gastric Cancer Risk Even After <i>H. Pylori</i> Eradication Tx

November 02, 2017

Results showed that PPI use correlated with elevated risk of GC (hazard ratio, 2.44; 95% confidence interval, 1.42 to 4.2), while histamine-2 receptor antagonist use was not associated with increased risk (hazard ratio, 0.72; 95% confidence interval, 0.48 to 1.07).

Long-Term Aspirin Use Linked to Reduced Incidence of GI Cancers

By October 31, 2017

Researchers compared patients who were prescribed aspirin over a long period (for at least six months, average duration of aspirin prescribed was 7.7 years) with non-aspirin users and assessed the incidences of a number of cancers.

Aemcolo Gets QIDP, Fast Track Designation for Travelers' Diarrhea

By October 31, 2017

In Phase 3 clinical trials involving patients with travelers' diarrhea, Aemcolo was found to be superior to placebo (P=0.0008) and non-inferior to ciprofloxacin.

Fish Consumption May Trigger Food Protein-Induced Enterocolitis

October 31, 2017

The number of reactions before diagnosis was four on average. The main symptoms at the debut were vomiting and vomiting with diarrhea (97.5 and 30%, respectively), which occurred in a mean time of 126.3 minutes after ingestion of the culprit fish.

Antiemetic Treatments

October 27, 2017

Antiemetic treatment chart including drug formulations, strengths, and usual doses for nausea/vomiting.

Varubi IV Approved for Delayed Chemotherapy-Induced Nausea/Vomiting

By October 26, 2017

Varubi, a highly selective and competitive antagonist of human substance P/neurokinin (NK-1) receptor, is already available as 90mg strength tablets.

Haloperidol Plus Conventional Tx Effective for Symptomatic Gastroparesis

By October 26, 2017

Haloperidol was superior to placebo in reducing nausea and pain.